Compugen Ltd (CGEN) Dividend History

Company News

• Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

  Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.

  Zacks Investment Research

  Featured Companies: ALXO XENE
• FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

  Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.

  Zacks Investment Research

  Featured Companies: ARQT HRTX RCKT
• Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

  Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.

  Zacks Investment Research

  Featured Companies: ALXO ANVS APLS
• PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug

  PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.

  Zacks Investment Research

  Featured Companies: ALXO ANVS PTCT
• Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting

  Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.

  Zacks Investment Research

  Featured Companies: ALXO ANVS COGT